MedTrace Logo

Photobiomodulation and Parkinson

NCT03811613 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-05-21

No results posted yet for this study

Summary

This study aimed to assess the effects of transcranial photobiomodulation in patients with Parkinson's disease (PD).

Conditions

  • Parkinson Disease

Interventions

OTHER

Transcranial photobiomodulation

Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)

Sponsors & Collaborators

  • University of Oviedo

    lead OTHER

Principal Investigators

  • Luis Santos, PhD · Department of Physical Education and Sport (University of León, Spain)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2018-03-30
Completion
2018-03-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03811613 on ClinicalTrials.gov